Sign in Subscribe
Cancer research

Breakthrough in Colon Cancer Diagnosis: Researchers Identify Potential Biomarker

Strategic Insights

— 2 min read

Researchers at the University of Chinese Medicine have made a significant discovery in the fight against colon cancer, identifying a potential biomarker for early detection. The study, published in Discover Oncology, found that the B9D2 gene, essential for ciliary function, is significantly upregulated in colon cancer patients, making it a promising candidate for non-invasive diagnostic methods.

Key Takeaways:

  • The study, the first to investigate the diagnostic potential of B9D2 in colon cancer, analyzed gene expression data from whole blood samples obtained from the GEO database.
  • Five key genes, including B9D2, CR2, DNMT3B, FOS, and PTGS2, were identified as having significant expression in peripheral blood, a non-invasive source.
  • B9D2 expression was significantly upregulated in colon cancer patients, with an AUC of 0.797 in ROC analysis, and was further validated in the GSE47756 dataset, with an AUC of 0.756.
  • This finding provides a foundation for the potential application of B9D2 as a biomarker for early detection in colon cancer.
  • Further experimental and clinical studies are needed to validate B9D2 as a reliable biomarker for early colon cancer detection and screening.
  • The study used bioinformatics and machine learning to uncover the novel role of B9D2 in early detection, with implications for clinical translation.
  • Gene expression data from whole blood samples were analyzed to identify differentially expressed genes (DEGs) associated with colon cancer.
  • Machine learning methods, including Random Forest (RF), LASSO regression, and Support Vector Machine Recursive Feature Elimination (SVM-RFE), were employed for feature selection and to evaluate the robustness and predictive power of the selected features.

Statistics:

  • 5 key genes (B9D2, CR2, DNMT3B, FOS, and PTGS2) were identified as having significant expression in peripheral blood.
  • B9D2 expression was significantly upregulated in colon cancer patients, with an AUC of 0.797 in ROC analysis.
  • B9D2 expression was further validated in the GSE47756 dataset, with an AUC of 0.756.
  • 16(1):1-18, the pages number of the research publication in Discover Oncology, the journal where the research was published.
  • The study was conducted by researchers at the Translational Medicine Research Center, Fifth Clinical Medical College of Henan, University of Chinese Medicine (Zhengzhou People's Hospital).
  • More information may be obtained by contacting Zhaorui Wang, corresponding author of the study.

Sources:

  • Discover Oncology, 2025, 16(1):1-18. The publisher for Discover Oncology is Springer.
  • https://doi-org.sdpl.idm.oclc.org/10.1007/s12672-025-03415-0. A free version of this journal article is available at this link.
  • NewsRx. Research from University of Chinese Medicine Yields New Findings on Colon Cancer (Diagnostic potential of the B9D2 gene in colorectal cancer based on whole blood gene expression data and machine learning). Health & Medicine Week. September 5, 2025; p 5447.

Read more